Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?

被引：0
作者：
Jing Xi
Cynthia X. Ma
机构：
[1] Washington University School of Medicine,Section of Medical Oncology, Division of Oncology, Department of Internal Medicine
[2] Washington University School of Medicine,Siteman Cancer Center
来源：
Current Oncology Reports | 2020年 / 22卷
关键词：
Metastatic breast cancer (MBC); Hormone receptor-positive (HR+) and HER2-negative (HER2−) breast cancer; Estrogen receptor-positive (ER+) breast cancer; CDK4/6 inhibitor; Endocrine therapy; Biomarkers; Sequencing of therapy; Resistance mechanisms; Clinical trials; PI3K inhibitor; mTOR inhibitor; FGFR inhibitor; CDK inhibitor; Aurora kinase inhibitor; RB1; PIK3CA; ESR1; Palbociclib; Abemaciclib; Ribociclib; Alpelisib; Everolimus; Selective estrogen receptor downregulator (SERD); Fulvestrant; Aromatase inhibitor; Targeted therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 496 条
[61]  
Gelbert LM(2015)Mechanisms of aromatase inhibitor resistance Nat Rev Cancer 15 261-675
[62]  
Cai S(2011)Mechanisms of endocrine resistance in breast cancer Annu Rev Med 62 233-369
[63]  
Lin X(2011)Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer Oncologist 16 404-226
[64]  
Sanchez-Martinez C(2016)Inhibition of Rb phosphorylation leads to mTORC2-mediated activation of Akt Mol Cell 62 929-1199
[65]  
del Prado M(2012)Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer N Engl J Med 366 520-1738
[66]  
Lallena MJ(2018)Randomized phase II trial of fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer resistant to aromatase inhibitor therapy: results of PrE0102 J Clin Oncol 36 1556-247
[67]  
Torres R(2012)Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study J Clin Oncol 30 2718-263
[68]  
Ajamie RT(2018)Combined inhibition of mTOR and CDK4/6 Is required for optimal blockade of E2F function and long-term growth inhibition in estrogen receptor-positive breast cancer Mol Cancer Ther 17 908-475
[69]  
Wishart GN(2019)Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2− advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): efficacy, safety, and biomarker results J Clin Oncol 37 1016-233
[70]  
Flack RS(2019)Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer N Engl J Med 380 1929-undefined
234567891011